30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

A Final Look at 2010 Results: Orthovita

$94.7MM, +2% (Biosurgery +6%; Vitoss -4%;
Vitoss Bioactive Foam +8%; U.S. Cortoss and
Aliquot $4MM, +263%)

4Q10 revenue: $23.4MM, -4% (Biosurgery $5.7MM, flat; Vitoss Bone Graft Substitute -6%, Vitoss
Bioactive Foam +3%, Vitoss Morsels +1%, U.S. Cortoss and Aliquot $0.8MM, +14%)

* 4Q sales reflect continued weakness in ortho and spine
* Realized modest increases of 1% to 2% in 4Q Vitoss and Biosurgery pricing; hemostatis pricing stable
* Losing Vitoss Classic Foam sales to lower-priced competition (major hardware suppliers heavily discounting standard bone grafts as part of larger package)
* Anticipates adjusting price for Vitoss Classic on case-by-case basis
* Recently launched Vitoss Bioactive Foam 2X (BA2X), has 50% more bioactive glass than
Vitoss BA
* Received FDA clearance of Vitoss BA Bimodal
* Launched new marketing to promote use of Vitagel hemostatis product in joint recon
* On track to launch cavity creation device (directional bone tamp) in mid-2011; expects clearance for balloon bone tamp in 2012
* Will file 510(k) for Cortoss for cranial defect repair in 3Q11
* Launching Bimodal by end of 2011 or early 2012 depending on performance of BA2X
* Developing new structural biomaterial BA PEEK with bioactive glass
* Hybrid sales force of 70-75 direct sales reps (DSRs), ~25 distributors and 40 independent agents
* DSRs provided ~60% of sales in 4Q